EUCTR2008-006710-23-SI进行中（未招募）不适用
Modulation of the immune response in patients with pancreatic tubular carcinoma - MIS-MIT
Blood Transfusion Centre of Slovenia0 个研究点开始时间: 2009年10月2日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. ECOG performace status 0, 1 or 2 at the time of randomization,
- •2. following R0 or R1 pancreatic tubular adenocarcinoma (larger than 2 centimeters) resection,
- •3. completed adjuvant gemcitabine chemotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. expected survival of less than three months,
- •2. R2 resection,
- •3. metastatic disease (M1 or N1).
研究者
相似试验
招募中
Unknown
Study on host immune response during treatment of patients with pulmonary nontuberculous mycobacterial diseasepulmonary nontuberculous mycobacterial diseaseJPRN-UMIN000049658Department of Respiratory Medicine, University of Tsukuba100
尚未招募
不适用
Analysis of patients treated with novel therapeutic agents for atopic dermatitisAtopic dermatitisJPRN-UMIN000044388Kindai University Hospital20
已完成
4 期
Assessment of Immune Modulation after use of NANO SOMACTRI/2021/10/037180DrPRRaghavan26
已完成
不适用
Characterization of the immune response in patients with urothelial cell carcinoma of the bladder and during the BCG immunotherapy of bladder cancerC67Malignant neoplasm of bladderDRKS00003700Chirurgische Universitätsklinik, Abteilung für Urologie410
已完成
Unknown
Efficacy and safety evaluation of PPCE for immune enhancement in healthy adults.KCT0008678MnF Korea30